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ABSTRACT
Glucocorticoids play an important role in the treatment of a number of
hematological malignancies, such as multiple myeloma. The effects of
glucocorticoids are mediated through the glucocorticoid receptor a, the
abundance of which can be modulated by alternative splicing of the
glucocorticoid receptor mRNA. Two splice variants of the glucocorticoid
receptor mRNA have been described: glucocorticoid receptor b, which
reportedly has a dominant negative effect on the actions of the glucocor-
ticoid receptor a, and glucocorticoid receptor P, of which the effects are
unknown. In this study, we have investigated the expression levels of these
two splice variants at the mRNA level in multiple myeloma cells and in a
number of other hematological tumors. Although the glucocorticoid re-
ceptor b mRNA was, if at all, expressed at very low levels, considerable
amounts (up to 50% of the total glucocorticoid receptor mRNA) glucocor-
ticoid receptor P mRNA was present in most hematological malignancies.
In transient transfection studies in several cell types and in multiple
myeloma cell lines, the glucocorticoid receptor P increased the activity of
the glucocorticoid receptor a. These results suggest that the relative levels
of the glucocorticoid receptor a and the glucocorticoid receptor P may
play a role in the occurrence of glucocorticoid resistance in tumor cells
during the treatment of hematological malignancies with glucocorticoids.
INTRODUCTION
GCs4 constitute an active component of chemotherapeutic
regimens for various B-cell lymphoid malignancies, such as
Hodgkin’s disease, indolent and aggressive NHL, MM, ALL, and
CLL (1–3). In contrast, AML or chronic myeloid leukemia and
preleukemic states such as the myelodysplastic syndromes usually
do not respond favorably to GC treatment (4). In lymphoid malignancies,
dexamethasone induces a rapid apoptotic response in vitro, which may be
antagonized by interleukin 6 and other cytokines (5). However, the
beneficial effects of GC therapy are limited because of the occurrence of
resistant tumor cell clones, which evolve during GC treatment. During
treatment, the malignant cells may develop resistance to the GC-mediated
cytolysis (1).
Genetic abnormalities of the GR are not a common cause of GC
resistance in hematological malignancies. Small deletions and point
mutations have been found in a highly resistant MM cell line (6) and
in other leukemic cell lines (7, 8). However, analysis of fresh leuke-
mia cell samples obtained from GC-resistant patients with CLL has
not revealed any GR point mutations (3).
Prolonged exposure of resistant cells to GCs has been reported to
up-regulate GR expression (9). However, in these MM cell lines, the
GC-induced response is not correlated with the number of GRs (9).
Even in highly refractory MM patients resistant to high doses of GCs,
the number of GRs/tumor cell is comparable with that in sensitive
tumor cells (10). Consequently, it seems likely that resistance to GCs
is mediated either by postreceptor mechanisms or that it is associated
with the presence of nonfunctional GR isoforms (9). Hence, the
question arises as to which mechanisms are required for GCs to
induce apoptosis. It is important to know whether, and to what extent,
abnormal GRs or GR isoforms are involved in the multistep process
leading to treatment-refractory disease. Several years ago, a variant
GR mRNA, designated GR-P, was observed in tumor cells obtained
from a GC-refractory myeloma patient (11). The GR-P protein is a
truncated GR protein of 676 amino acid residues (Ref. 11; Fig. 1).
GR-P differs from GR-a, which is the active form of the GR, and the
well-known natural splice variant GR-b (12), because the exons 2–7
and a part of intron 7 encode it and the exons 8 and 9 are missing.
GR-a uses exons 2–8 and part of 9a as a coding region, whereas
GR-b uses the exons 2–8 and part of 9b as a coding region, as is
indicated in Fig. 1. In this study, we demonstrate that GR-P mRNA is
present in fresh tumor cells obtained at diagnosis from patients with
MM, ALL, or NHL, who were sensitive to treatment with GCs. In
contrast to this, the expression of the GR-b splice variant was very
low or undetectable in these samples. Transfection studies in several
different cell lines demonstrated that GR-P increases the activity of
GR-a in COS cells and in HeLa cells but not in CHO cells. This
suggests that cell-specific factors play a role in this process and that
the ratio of GR-P:GR-a 1 GR-b mRNA may reflect different grades
of GC responsiveness, with a higher ratio corresponding to a higher
sensitivity.
MATERIALS AND METHODS
Tumors and Tumor Cell Lines. After having obtained approval from
the local Medical Ethics Committee and informed consent from the pa-
tients, fresh bone marrow cells were collected at diagnosis from the
posterior iliac crest of 16 previously untreated patients with MM. These
patients were included in a clinical study protocol of the Dutch Hemato-
Oncology Group (HOVON). After marrow collection, these MM patients
were treated with 3 cycles of i.v. vincristine, Adriamycin, and dexametha-
sone. Thereafter, the clinical response was assessed according to the
criteria of the Southwestern Oncology Group. For the present analysis,
patients were classified as responders (those who had achieved a complete
response or a partial response) and nonresponders. To determine the pattern
of GR expression in MM patients as compared with other hematological
malignancies, we also studied tumor cells obtained from the bone marrow
of untreated patients with ALL (n 5 5) and NHL (n 5 5), who subsequently
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showed a clinical response to GC treatment and from patients with AML
(n 5 5), a disease that is unresponsive to GC treatment. Bone marrow
aspirates were collected in Hanks’ HEPES medium and purified using
buffy coat or a Ficoll-Hypaque gradient and adherence depletion. Samples
with ,80% tumor cells as determined by microscopy were discarded.
Normal lymphocytes were obtained from healthy volunteers and purified
by Ficoll-Hypaque gradient centrifugation.
RNA Isolation. Total RNA was isolated using the Trizol standard protocol
(Life Technologies, Inc., Gaithersburg MD). Dr. Gert-Jan van Steenbrugge
(Department of Urology, Erasmus University) kindly provided total RNA from
control tumor cell lines and prostate carcinoma xenografts.
RT-PCR Assays. One mg of total RNA was reverse transcribed using 1
pmol of oligo-dT primers (Pharmacia Biotech, Roosendaal, the Netherlands),
2.0 units Superscript reverse transcriptase (Life Technologies, Inc., Gaithers-
burg, MD), 0.5 unit RNasin (Promega Benelux, Leiden, the Netherlands), and
1 mM deoxynucleotide triphosphates in reverse transcriptase buffer (Life
Technologies, Inc.). The total volume was adjusted with distilled H2O to 20 ml.
One-tenth of the reverse transcriptase reaction mixture was used directly for
the PCR reaction in a total volume of 20 ml, with 1.0 unit of SuperTaq
polymerase (Sphaero Q; Leiden, the Netherlands), 300 nM of the relevant
primers (see below), and SuperTaq PCR buffer (Sphaero Q). The sequences of
the oligonucleotide primers 1, 2, and 3 (Pharmacia Biotech, Roosendaal, the
Netherlands) to discriminate GR-P from the total GR message, shown in Fig.
1, have been described previously (11). The sequences of the oligonucleotide
primers 4, 5, and 6 (Pharmacia Biotech) to discriminate GR-a from GR-b (Fig.
1) are as follows: primer 4, 59-GAATGACTCTACCCTGCATG-39; primer 5,
59-TTTCCATTTGAATATTTTGG-39; and primer 6, 59-GCTTTCTGGTTT-
TAACCACA-39. Upstream primer 4 is common to both GR-a and GR-b and
hybridizes to exon 7 sequences, encoding part of the hormone-binding domain
of the receptor. The downstream primers for GR-a (primer 5) and GR-b
(primer 6) are within exon 9a and exon 9b, respectively. A trace amount (2
mCi) of [32P]dATP was added to the mixture. Samples were heated for 5 min
at 94°C, and then 35 cycles were carried out, consisting of 1 min at 94°C, 1.5
min at 50°C, and 1.5 min at 72°C. This was followed by a final 10-min
extension at 72°C. The PCR reaction products were separated on a 6%
nondenaturing polyacrylamide gel, and the gel was dried and exposed to X-ray
film (Fuji, Tokyo, Japan) for signal detection and quantification.
Signal Quantification. X-ray films were scanned using a Hewlett Packard
Scanjet II CX, and signal intensities were measured using a computer program
written and kindly provided by Dr. R. Docter of the Department of Internal
Medicine.
Hormones and Substrates. Dexamethasone was purchased from Pharma-
cin (Zwijndrecht, the Netherlands). D-Luciferin was purchased from Sigma
Chemical Co. (St. Louis, MO).
Reporter Genes and Expression Vectors. Dr. Ronald Evans (The Salk
Institute, La Jolla, CA) kindly provided the pRShGRa expression vector. The
hGRd expression vector, pcDNA3-hGRd, was constructed by replacing the
ClaI/XhoI fragment of pcDNA3-hGRa with hGRd cDNA sequence 1525–
2331 from pRSV-hGRd as ClaI/XhoI fragment. pRSV-hGRd was in turn
derived by replacing the ClaI/XhoI fragment of pRSVhGRa (R. Evans) with
hGRd cDNA sequence 1101 to 2331d. The 59 sequence of the PCR product
was common to all GR splice variants and contained a unique ClaI site. The
39 primer incorporated an XhoI site at the 39 end. The pcDNA3.1 vector,
containing the CMV promoter was purchased from Invitrogen (Groningen, the
Netherlands). The MMTV-LUC reporter plasmid was kindly provided by
Organon (Oss, the Netherlands).
Cell Culture and Transfections. Monkey kidney (COS-1), CHO, and
human cervical epithelial carcinoma cells (HeLa) were maintained in DMEM-
Ham’s F-12 tissue culture medium (Life Technologies, Inc.) supplemented
with 5% charcoal dextran-treated FCS (Life Technologies, Inc.). The RPMI
8226 parent cell line was kindly provided by Dr. W. S. Dalton (Lee Moffitt
Cancer Center, Tampa, FL). These cells were grown in suspension culture in
DMEM with 10% DCC-FCS and 0.1% gentamicin. The UM3 cell line was
derived and provided by Dr. H. M. Lokhorst (Department of Hematology,
University Hospital Utrecht, the Netherlands). These cells were grown in
suspension culture in RPMI 1640 with 10% DCC-FCS and 0.1% gentamicin.
For transcription regulation studies, cells were plated at 6.0 3 104 cells/well
(3.5 cm2; COS-1 and HeLa cells) or at 3 3 104 cells/well (CHO cells). They
were grown for 24 h and transfected overnight by calcium phosphate precip-
itation, as described previously (13, 14). For LUC assays, cells were trans-
fected with 10 ng/well of pRShGRa and either 0, 1, 5, 10, 50, or 100 ng/well
pcDNA3hGRd plasmid, containing the hGR-P receptor, driven by the CMV
promoter. All transfections were supplemented to a total of 100 ng/well of
CMV promoter-containing plasmid with the pcDNA3.1 plasmid. In addition to
this, 100 ng/well of MMTV-LUC plasmid were added. pTZ carrier DNA was
added to bring the total amount of DNA to 2 mg/well. After an incubation
period of 24 h, dexamethasone was added, and after another 24 h, the cells
were harvested for the LUC assay, as described previously (13, 14). RPMI
8226 and UM3 MM cells at 105 cells/well were transfected in suspension using
the FuGENE transfection reagent (Roche Diagnostics Nederland B.V., Alm-
ere, the Netherlands) according to the supplier’s protocol with a FuGENE:
DNA ratio of 6:1. For LUC assays, cells were transfected with 24 ng/well of
pRShGRa and either 0, 15, 30, 60, 120, or 240 ng/well pcDNA3hGRd
plasmid, containing the hGR-P receptor, driven by the CMV promoter. All
transfections were supplemented to a total of 240 ng/well of CMV promoter-
containing plasmid with the pcDNA3.1 plasmid. In addition to this, 100
ng/well of MMTV-LUC plasmid was added. pTZ carrier DNA was added to
bring the total amount of DNA to 2 mg/well. After an incubation period of
24 h, dexamethasone (100 nmol/l) was added, and after another 24 h, the cells
were harvested for the LUC assay, as described previously (13, 14).
Statistical Analysis. The data resulting from the transfection studies were
analyzed by ANOVA, and when significant differences between groups were
present, multiple comparisons were carried out using the Student-Newman-
Keuls test.
Fig. 1. Glucocorticoid receptor mRNA and
protein variants and PCR primers. GR mRNAs
resulting from alternative splicing of the GR gene
and their derived GR proteins are shown. GR-b
differs from GR-a by usage of exon 9b as a
coding region, and GR-P is an mRNA encom-
passing part of intron 7 but lacking exons 8 and
9. N-TERM, NH2-terminal (variable) domain;
DBD, DNA binding domain; HBD, hormone
binding domain. The location of the PCR primers
used and the lengths of the amplified fragments
are indicated under the mRNA structure. Primer
pairs 1–2 versus 1–3 were used to distinguish
GR-a 1 GR-b from GR-P. Primer pairs 4 –5
versus 4 – 6 were used to distinguish GR-a from
GR-b.
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RESULTS
Expression of GR-P in Multiple Myeloma. We have screened
bone marrow samples, obtained before the start of treatment from 16
patients with MM for the presence of mRNAs, encoding the GR
variants. Of these patients, 8 (Fig. 2, Lanes 10, 11, 13, 14, and 16–19)
had shown a rapid response to vincristine/Adriamycin/dexamethasone
combination therapy, whereas 8 patients responded only slowly or
were refractory (Fig. 2, Lanes 1, 4–9, and 15). The expression of
GR-P varied drastically among the patients, and in some cases, GR-P
mRNA levels exceeded those of GR-a 1 GR-b, e.g., patient 17, albeit
that in this patient the total signal was rather low. Quantification of
GR-P versus GR-a 1 GR-b mRNA ratios did not show a clear
difference between sensitive or less sensitive MM patients. Separate
analysis of the levels of GR-a and GR-b mRNAs showed that GR-b
was expressed in all samples at 1–5% of the GR-a message (not
shown). In five samples of normal lymphocytes, GR-P constituted
,20% of the total GR message (GR-a 1 GR-b 1 GR-P). An
example is shown in Fig. 2, Lane CON.
Expression of GR-P in Other Hematological Malignancies. Ex-
pression levels of the GR-P variant were also determined in purified
tumor cells obtained from the bone marrow samples of patients with
ALL, AML, and NHL. Substantial levels of GR-P expression were
found in many of the samples (Fig. 2). However, as was found in the
MM samples, there was a considerable variation in GR-P expression.
In ALL patients, the relative level of GR-P ranged from 23% of the
total GR message (patient 21) to 54% (patient 23). NHL patients all
expressed GR-P at very high levels, as can be observed in patients 32,
33, and 34 (44, 41, and 43% of the total GR message, respectively).
In samples from patients with AML, a hybrid expression pattern of
GC variants was observed. Although only four of five samples could
be analyzed successfully, apparently 2 patients exclusively expressed
either GR-a only (patient 28) or GR-P only (patient 26), whereas in
two other samples, both GR-a and GR-P were detected (patients 29
and 30). In all of these samples, GR-b expression was undetectable
under these conditions.
Expression of GR-P in Other Tumors. In samples from paragan-
gliomas, consisting of very slowly dividing cells as opposed to the
other tumors, which consist of more rapidly dividing cells, no expres-
sion of GR-P was detected (Fig. 2). In ovarian carcinoma and mam-
mary carcinoma cell lines, GR-P was expressed at constant levels, at
;27% of the total GR mRNA, which is slightly higher than that found
in normal lymphocytes (the highest level found was 20%). In the liver
cell line HepG2 and in the androgen-sensitive prostate carcinoma
cell-line LNCaP-FGC, GR-P was expressed at low levels, comparable
with those seen in normal lymphocytes. In prostate carcinoma xe-
nografts, GR-P expression varied from 12 to 30% of the total message
(Fig. 2). GR-b was not expressed in these tumors.
Effect of GR-P on Cell Type-specific Activity of GR. To study
the effect of GR-P on GR-a activity, transient transfection assays
were performed using several cell lines of different origins. COS-1
cells were cotransfected with 10 ng of hGR-a expression plasmid and
increasing concentrations (0–100 ng) of GR-P expression plasmid as
indicated in Fig. 3A. In the absence of GR-P, dexamethasone stimu-
lated GR-a-mediated luciferase expression ;100-fold. When GR-P
was cotransfected with GR-a, it induced a significant concentration-
dependent increase in the dexamethasone-induced luciferase activity,
resulting in a maximal stimulation of 2.5-fold over the stimulation by
dexamethasone in the absence of GR-P (P , 0.05). In HeLa cells, the
stimulatory effect of GR-P was also observed when GR-a was co-
transfected (P , 0.01; Fig. 3B). In the absence of exogenous GR-a in
HeLa cells, which have a functional endogenous GR-a, a similar trend
was observed (P , 0.05; Fig. 3D). Induction levels in HeLa cells in
the absence of exogenous GR-a were one third of those observed
when GR-a expression plasmid was present (results not shown). In
contrast to the effects of GR-P in COS-1 and HeLa-cells, GR-P had an
inhibitory effect in CHO cells (Fig. 3C). When CHO cells were
cotransfected with GR-P and GR-a, a reduction of the maximal
stimulation by 50% was observed, relative to the dexamethasone-
induced stimulation in the absence of GR-P (P , 0.01; Fig. 3C).
However, in the absence of cotransfected GR-a, CHO cells showed
no response to dexamethasone (Fig. 3E), despite the presence of
endogenous GR-a in these cells. Most importantly, cotransfection of
GR-P also potentiated the GR-a-mediated dexamethasone effect sig-
nificantly (P , 0.01; Fig. 4) in two MM cell lines, RPMI 8226-S (Fig.
4A) and UM3 (Fig. 4B).
DISCUSSION
The cause of GC resistance in hematological malignancies is un-
clear. Direct involvement of the GR may include genetic alterations in
the GR gene or altered expression of the GR or its splice variants.
Indeed, genetic alterations in the GR have been reported to occur in a
MM cell line (6); a deletion of 8 bp in the 39 untranslated region (exon
9a) of the GR gene was found in the MM cell line U266. This 8-bp
sequence contained an estrogen response element half site (59-
TGACCT-39), which may serve to interact with regulatory factors,
including the estrogen receptor (6). Analysis of a number of GC-
sensitive and -resistant cell lines derived from the clonal leukemic cell
line CEM-C7 suggests that mutations in the GR gene frequently cause
glucocorticoid resistance in vitro (7, 8). The lack of apoptotic re-
sponses to GC in GC resistant cells is activator protein-1 independent
but may involve the less effective induction of a labile nuclear
factor-kB inhibitory factor (8). We have shown recently that muta-
tions in the GR gene of patients with generalized GC resistance may
achieve a differential interaction with some of these factors (13).
One report has addressed the question as to whether mutations in
the human GR gene can also account for the development of refrac-
toriness to GC treatment in CLL patients (3). However, none of the
resistant patients studied revealed any additional mutations in the GR
gene in their tumor cells. The results suggested that mechanisms other
than altered ligand or DNA binding of the receptor should be respon-
Fig. 2. The expression of GR-a 1 GR-b and GR-P mRNAs in several types of
hematological malignancies and in solid tumors. Top panel, MM (Lanes 1–21). RT-PCR
showing GR-a 1 GR-b (top signal) and GR-P (bottom signal) levels. CON, normal
lymphocytes; DNA, genomic DNA negative control. Lane numbers are patient numbers:
Lanes 1–9 and 15 are GC-resistant patients; the others are GC sensitive. Material from
patients 2, 3, and 12 (the empty lanes) failed to amplify. Middle panel, RT-PCR showing
GR-a 1 GR-b and GR-P levels in leukemic cells and in paragangliomas. AML, acute
myeloid leukemia (material from patient 27, the empty lane, failed to amplify). Bottom
panel, RT-PCR showing GR-a 1 GR-b and GR-P levels in an ovarian tumor cell line
(OV-CAR), in several mammary tumor cell lines, in HepG2 cells (HepG2), in LNCaP-
FGC (FGC) cells, and in prostate carcinoma xenografts, respectively.
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sible for the lack of response to dexamethasone therapy (3). Indeed,
studies in three MM cell lines, OPM-2, RPMI 8226, and OPM-1,
sensitive, partially sensitive, and resistant to GCs, respectively, re-
vealed that the number and affinity of GRs in these cell lines did not
predict their response to GCs (9). The resistance to glucocorticoid
inhibition of cell growth in the OPM-1 and RPMI 8226 cell lines may
thus be a postreceptor mechanism. Multidrug-resistant MM cell lines
R10, R40, and R60 exhibited a decrease of their absolute GR level
upon doxorubicin treatment (15). In the relatively doxorubicin-sensi-
tive cell line R10, this reduction was not counteracted by GC treat-
ment. However, in the highly doxorubicin-resistant R40 and R60 cell
lines, GR mRNA levels were up-regulated upon stimulation with
GCs. GC treatment may thus be an alternative mechanism for the
reversal of multidrug resistance (15).
A splice variant of the hGR termed GR-P has been identified in
MM patients (11), and we have investigated expression of its mRNA
in untreated hematological malignancies. Relative to its expression in
normal peripheral blood lymphocytes (10–20% of the total GR
mRNA), we observed a consistently high expression of this isoform in
myeloma plasma cells. GR-P mRNA was also present in ALL, NHL,
and to a lesser extent in AML. These levels of expression of the GR-P
suggest a potential role for the GR-P, not only in highly refractory
MM cells, as has been suggested (11), but also in relatively sensitive
cells. Moreover, GR-P expression was also found at considerable
levels (45–55% of the total GR mRNA) in lymphocytes isolated from
normal bone marrow aspirates (not shown).
These data indicate that the GR-P form is uniformly present in
malignant hematological cells at diagnosis. Thus far, its role in these
cells is difficult to assess. In our small series of MM patients, refrac-
toriness to GC therapy did not seem to be associated with grossly
altered ratios of the GR-P:GR-a 1 GR-b mRNA (Fig. 2). Possibly,
GC treatment may induce some changes in the level of GR-P expres-
sion later during the course of the disease. The present data indicate
that GR-P expression is not a phenomenon observed exclusively in
highly refractory cases of myeloma, as was assumed in earlier studies
(11). Although we have focused on MM in this study, other GC-
responsive diseases such as ALL and NHL were also included, and
essentially the same pattern was observed. In contrast, AML patients
showed a more variable pattern, which seems in line with the clinical
observation of lower or absent response of these tumors to GC
treatment.
GR-P was also found at a variable degree of expression in a panel
of other tumors, in xenografts from prostate carcinomas, and in tumor
cell lines from ovarian carcinoma, mammary carcinoma, HepG2 cells,
and LNCaP-FGC-cells. These data indicate that high levels of GR-P
expression are not restricted to hematological malignancies and may
be involved in the GC response of tumors originating from different
tissues. Interestingly, the GR-P variant was absent in benign neuro-
endocrine tumor cells (paragangliomas).
Because it was observed that GR-b was expressed at very low
levels in MM and could not be detected at all in other hematological
malignancies or in solid tumors, it can be concluded that the GR-P
splice variant is the only one that is predominantly generated in
(hematological) malignancies.
We and others (14, 16, 17) have shown that GR-b does not inhibit
GR effects in COS-1 and in other cells, whereas other groups have
shown that the GR-b acts as a dominant inhibitor of GR action (12,
18). The observation that the GR-P splice variant investigated in this
study stimulates GR activity in COS-1, HeLa, and MM cells while it
Fig. 3. Cell type-specific effects on GR-a activity by GR-P. COS-1 (A), HeLa cells (B
and D), and CHO cells (C and E) were transfected with increasing concentrations of the
GR-P encoding plasmid pCDNA3hGRd (0–100 ng/well) as indicated, in the presence
(A–C) or absence (D and E) of 10 ng/well of the GR-a-encoding plasmid pRShGRa.
Additionally, 100 ng/well of the reporter plasmid pMMTV-LUC was transfected (A–E),
and the pCDNA3.1 plasmid was cotransfected to obtain a constant total concentration of
CMV promoter-containing vector of 100 ng/well in each transfection (A–E). Luciferase
activity was measured in supernatants from ligand-untreated cells (E) and in supernatants
from cells treated with dexamethasone (100 nmol/l; M). LUC activity is shown as a
percentage of control values (in the presence of dexamethasone and absence of transfected
GR-P), set as 100%. Data are the means of three transfection experiments, each carried out
in triplicate; bars, SD. Values that were significantly different (Newman-Keuls test) from
the control values (without GR-P) are indicated by . (P , 0.05) and F (P , 0.01).
Fig. 4. The effects of GR-P in RPMI 8226-S cells and in UM3 multiple myeloma cell
lines. RPMI 8226-S cells (A) and UM3 cells (B) were transfected with increasing
concentrations of the GR-P-encoding plasmid pCDNA3hGRd (0–240 ng/well) as indi-
cated, in the presence of 24 ng/well of the GR-a-encoding plasmid pRShGRa. Addition-
ally, 100 ng/well of the reporter plasmid pMMTV-LUC was transfected, and the
pCDNA3.1 plasmid was cotransfected to obtain a constant total concentration of CMV
promoter-containing vector of 240 ng/well in each transfection. LUC activity was meas-
ured in supernatants from ligand-untreated cells (E) and in supernatants from cells treated
with dexamethasone (100 nmol/ml; M). LUC activity is shown as a percentage of control
values (in the presence of dexamethasone and absence of transfected GR-P), set as 100%.
Data are the means of three (A) or two (B) transfection experiments, each carried out in
triplicate; bars, SD of the mean. Values that were significantly different (Newman-Keuls
test) from the control values (without GR-P) are indicated by . (P , 0.05) and F
(P , 0.01).
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inhibits GR effects in CHO cells is new. Our experiments in the RPMI
8226-S and UM3 myeloma cell lines (Fig. 4) demonstrate that a
specific dexamethasone response is mediated through GR-a, and that
GR-P may up-regulate activation of the dexamethasone effect. This
finding may be of important clinical relevance because of the ob-
served wide variation of GR-P expression in naive myeloma cells
obtained from patients.
The effects of GR-P observed in our transfection experiments are
relatively small, 2.5-fold increases only at relatively high concentra-
tions of added GR-P expression plasmid. However, it is possible that
in this system the amount of cotransfected GR-a is so high that
relatively much GR-P is necessary to make its effects visible. More-
over, the effects observed in CHO cells occur already when GR-a and
GR-P are transfected in equal quantities (10 ng each; see Fig. 3C).
Such equal amounts of both splice variant mRNAs have also been
observed in several tumor samples (e.g., Fig. 2, Lanes 17, 23, and 34).
In contrast to the situation in these transfection experiments, where a
constant amount of GR-a was used in the presence of increasing
concentrations of GR-P, the situation in vivo is different. There the
generation of each copy of GR-P mRNA proceeds at the expense of
a copy of GR-a mRNA. Reductions in the number of GR-a mole-
cules/cell have been shown previously to reduce glucocorticoid sen-
sitivity (19).
The mechanism by which the effects of GR-P occur are unknown.
However, the differences observed between the cell types suggest that
the specific cellular environment plays a role in determining the
nature of these effects. GR-P may have a conformation that favors
dimerization to ligand-bound GR-a, depending upon the relative
abundance of the GR-a and GR-P proteins, upon which the dimer
translocates to the nucleus to stimulate transcription of target genes in
a more efficient manner compared with regular GR-a homodimers.
Alternatively, the balance between GR-a and GR-P formation in the
in vivo context may modulate the effects of glucocorticoids. In this
way, decreased expression of GR-P in chemotherapy-resistant he-
mato-oncological tumor cells could explain enhanced resistance to
glucocorticoid therapy. Clinically, such mechanisms are of great
importance, because the development of resistance to GCs during
treatment contributes to treatment failure. Also, here we have only
investigated one mode of glucocorticoid action with respect to the
effects of GR-P, stimulating effects of the GR operating via direct
interaction of the GR dimer with discrete sequences in the promoter
region of the target gene (the MMTV glucocorticoid-responsive ele-
ments). It will be interesting to investigate the role of GR-P in systems
designed to dissect other modes of GR action, such as in activator
protein-1- and nuclear factor-k-B-mediated glucocorticoid signal
transduction. We have shown previously (13) that several mutations in
the GR gene, responsible for generalized GC resistance, exhibit dif-
ferent response profiles in such systems. Recently, it was shown that
GR-P does bind to the promoter region of the proopiomelanocortin
gene (20) but apparently does not repress gene expression in that
context. We are currently also investigating which external signals
influence the relative abundance of the GR splice variants in periph-
eral mononuclear leukocytes and if changes in this distribution affect
the regulation of endogenous glucocorticoid-regulated genes, such as
several cytokine genes.
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